Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

NARecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

May 22, 2025

Primary Completion Date

March 15, 2027

Study Completion Date

March 15, 2028

Conditions
Hepatocellular Carcinoma(HCC)
Interventions
DRUG

FOLFOX4

FOLFOX4 was administered by oxaliplatin 85 mg/m² d1+ leucovorin 200 mg/m² d1-2+ fluorouracil 400 mg/m² 2 h→ 600 mg/m² 24 h d1-2 q2w, with a total of 4 cycles

DRUG

Adebrelimab

Adebrelimab 1200mg, intravenous infusion, every 3 weeks

DRUG

Apatinib

Apatinib 250mg, oral, once daily.

DRUG

Icaritin

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

DRUG

SHR-1701

SHR1701,30mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

DRUG

QL1706

QL1706,5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

DRUG

Bevacizumab

Bevacizumab 7.5mg, intravenous infusion, once every 3 weeks.

PROCEDURE

HAIC

Hepatic Arterial Infusion Chemotherapy

PROCEDURE

Local treatment

Local treatment of oligo-metastases.

DRUG

The original treatment regimen

Continue the original targeted therapy combined with immunotherapy. dosage, dosage form,frequency of administration was the same as before.

Trial Locations (1)

210000

RECRUITING

China Pharmaceutical University Affiliated Nanjing Tianyinshan Hospital, Nanjing

All Listed Sponsors
lead

Nanjing Tianyinshan Hospital

OTHER